PMGC Holdings Stock Price, News & Analysis

PMGC Holdings (NASDAQ: ELAB) will effect a 1-for-4 reverse stock split of its common stock effective Jan 6, 2026 at 9:00 AM ET. Every four issued or authorized shares will be consolidated into one share, with fractional-share holders receiving one full share for each fractional portion.

The trading symbol remains ELAB and the new CUSIP is 73017P409. Outstanding equity awards, options, reserved shares, and warrants and their exercise prices will be proportionally adjusted. Immediately prior to the split the company had approximately 2,014,852 issued and outstanding shares; following the split it expects about 503,713 shares outstanding, subject to customary rounding and adjustments. Certificate holders can exchange through VStock Transfer.

PMGC Holdings (NASDAQ: ELAB) will effect a 1-for-4 reverse stock split of its common stock at 9:00 AM ET on January 6, 2026. Every four issued or authorized shares will be consolidated into one share and fractional entitlements will be converted into whole shares.

The trading symbol will remain ELAB and the company will use a new CUSIP 73017P409. Outstanding awards, options, reserved shares, and warrant shares and exercise prices will be adjusted proportionally. Transfer agent VStock Transfer will handle certificate exchanges.

The company expects approximately 2,034,882 shares outstanding immediately prior to the split and about 508,721 shares outstanding immediately following the split.

PMGC Holdings (Nasdaq: ELAB) said its subsidiary AGA Precision Systems achieved AS9100 certification on Dec. 22, 2025, the quality management standard for aerospace, defense and space manufacturing.

The company says AS9100 confirms a structured, process-based quality system that may enable AGA to support more complex, regulated programs and deepen relationships with existing aerospace, defense and space customers, potentially driving increased demand and recurring work. The company is also researching integration of humanoid robotics and advanced robotic automation into manufacturing, but noted these initiatives are under evaluation with no assurance they will occur or deliver expected benefits.

NorthStrive Biosciences (NASDAQ:ELAB) initiated Phase III of its AI Development Program with Yuva Biosciences to move AI-prioritized small-molecule candidates into experimental validation targeting muscle preservation via mitochondrial function.

Phase III will generate biological data including cytotoxicity screening and ANT1 expression testing at multiple timepoints, leveraging an exclusive mitochondrial biogenesis dataset and YuvaBio’s MitoNova™ AI classifier to focus testing on the most promising candidates. The work is intended to accelerate discovery and reduce compounds advanced for further development. Phase III is expected to take approximately 6 to 9 weeks.

PMGC Holdings (NASDAQ: ELAB) congratulated General Enterprise Ventures (NYSE American: CITR) on its uplisting to the NYSE American on December 4, 2025 and highlighted PMGC Capital's equity investment in GEVI.

PMGC said the uplisting should increase GEVI's visibility and access to institutional capital as it scales CitroTech, an EPA Safer Choice and UL GreenGuard Gold certified, non‑toxic fire‑inhibition technology with 80+ global patents and 18+ environmental accreditations. Target markets include commercial/industrial protection, lumber treatment, energy storage systems, transportation, defense, and wildfire mitigation.

PMGC Holdings (NASDAQ: PMGC) announced that its wholly owned subsidiary AGA Precision Systems completed ITAR registration and is in compliance with U.S. export‑control rules administered by the State Department’s Directorate of Defense Trade Controls.

The registration enables AGA to pursue defense and aerospace programs requiring ITAR compliance, enhances its eligibility as a qualified supplier to Tier 1 defense contractors and aerospace OEMs, and supports PMGC’s roll‑up strategy to expand into high‑value, defense‑related manufacturing. AGA operates manufacturing sites in Santa Ana and Hawthorne, California, providing advanced CNC machining and engineering services for complex metal and composite aerospace, defense and industrial components.

PMGC Holdings (NASDAQ: PMGC) announced that its subsidiary AGA Precision Systems acquired all operating assets of Indarg Engineering in Hawthorne, California, effective Oct 28, 2025.

The acquisition adds a four-decade precision CNC machining platform serving aerospace, defense, medical, and automotive sectors, expands AGA’s U.S. manufacturing footprint beyond Santa Ana, and will rebrand the Hawthorne site under the AGA name. Joel Alvarez, former owner and president of Indarg, will continue as General Manager to maintain customer continuity and operational leadership. Transaction terms were not disclosed.

PMGC Holdings (Nasdaq: ELAB) said its operating subsidiary AGA Precision Systems reported a sales backlog of approximately $711,000 in current orders logged into Sage100 and is bidding on additional RFQs totaling over $700,000. AGA purchased two high-performance CNC machines (YCM RX65 5-axis and CMZ TA30Y turning center) with delivery expected in Q4 2025 to expand precision machining for aerospace and defense materials. AGA now employs more than 15 full-time staff and anticipates doubling production capacity over the next year. The company rebranded AGA and launched a new website at www.AGAPrecision.com. Backlog and quotation figures are internally prepared, unaudited, and subject to change.

Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has completed Phase II of its AI Development Program with Yuva Biosciences. The collaboration leverages YuvaBio's proprietary MitoNova™ AI platform to discover potential treatments for obesity and cardiometabolic diseases.

During Phase II, YuvaBio analyzed 12 curated libraries of compounds focused on obesity, cardiometabolic disorders, and lipid & glucose metabolism. The AI platform screened these compounds to evaluate their predicted impact on muscle preservation and metabolic health. YuvaBio has now delivered a shortlist of small molecule candidates to Northstrive for biological validation and potential clinical development.